These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients. Herzberg GZ, Rossi AF, Courtney M, Gelb BD. J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760 [Abstract] [Full Text] [Related]
5. What else distinguishes cellular rejection grade 1A from 0? Annexin V and BCL in elective biopsies received from heart transplant recipients. Zeglen S, Nozynski J, Wozniak-Grygiel E, Zakliczynski M, Kucewicz-Czech E, Laszewska A, Cichoracka A, Zembala M. Transplant Proc; 2009 Oct; 41(8):3198-201. PubMed ID: 19857709 [Abstract] [Full Text] [Related]
6. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Slavcev A, Lácha J, Honsová E, Sajdlová H, Lodererová A, Vitko S, Skibová J, Striz I. Transpl Immunol; 2005 Jun; 14(2):117-21. PubMed ID: 15935302 [Abstract] [Full Text] [Related]
8. High pretransplantation soluble CD30 levels: impact in renal transplantation. Giannoli C, Bonnet MC, Perrat G, Houillon A, Reydet S, Pouteil-Noble C, Villar E, Lefrançois N, Morelon E, Dubois V. Transplant Proc; 2007 Oct; 39(8):2574-5. PubMed ID: 17954178 [Abstract] [Full Text] [Related]
9. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients. Wang D, Wu WZ, Chen JH, Yang SL, Wang QH, Zeng ZX, Tan JM. Transpl Immunol; 2010 Feb; 22(3-4):115-20. PubMed ID: 20036333 [Abstract] [Full Text] [Related]
10. Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols. Hire K, Hering B, Bansal-Pakala P. Transpl Immunol; 2010 Aug; 23(4):209-14. PubMed ID: 20600901 [Abstract] [Full Text] [Related]
11. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection. Ayed K, Abdallah TB, Bardi R, Abderrahim E, Kheder A. Transplant Proc; 2006 Sep; 38(7):2300-2. PubMed ID: 16980071 [Abstract] [Full Text] [Related]
14. Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation. Zwirska-Korczala K, Zakliczyński M, Berdowska A, Zembala M, Jochem J, Gajewska K. J Heart Lung Transplant; 2005 Apr; 24(4):411-5. PubMed ID: 15797741 [Abstract] [Full Text] [Related]
15. Soluble CD30 as a prognostic factor for outcome following renal transplantation. Platt RE, Wu KS, Poole K, Newstead CG, Clark B. J Clin Pathol; 2009 Jul; 62(7):662-3. PubMed ID: 19561239 [Abstract] [Full Text] [Related]
19. Value of soluble CD30 in liver transplantation. Fábrega E, Unzueta MG, Cobo M, Casafont F, Amado JA, Romero FP. Transplant Proc; 2007 Sep; 39(7):2295-6. PubMed ID: 17889168 [Abstract] [Full Text] [Related]
20. Evaluation of soluble CD30 as an immunologic marker in heart transplant recipients. Spiridon C, Hunt J, Mack M, Rosenthal J, Anderson A, Eichhorn E, Magee M, Dewey T, Currier M, Nikaein A. Transplant Proc; 2006 Dec; 38(10):3689-91. PubMed ID: 17175368 [Abstract] [Full Text] [Related] Page: [Next] [New Search]